Imexpharm Pharmaceutical Joint Stock Company recently held its Annual General Meeting for 2025, passing a revenue plan that increases by 19% to reach 2,981 billion VND and a pre-tax profit of 493.5 billion VND – an increase of 22% compared to last year. Imexpharm will invest in the IMP5 factory with a capacity of 1.4 billion products, aiming to become a leading pharmaceutical company in Asia focused on high-tech products. The company plans to launch 16 new products in 2025 targeting high-tech segments including antibiotics and complex treatments like cardiovascular, digestive, and diabetes, which have a large market scale.
The Board of Directors also decided to reduce the dividend ratio from 20% to 5% to reinvest in the new factory project. SK Group, which currently holds 65% of Imexpharm’s shares, is in the process of restructuring its investment portfolio and may change its ownership ratio at Imexpharm in the future. The company is also expanding collaboration with pharmacy chains to boost sales and profitability.
Leave a Reply